The Signaling Pathways in Obesity-related Complications

Overview

Journal J Cell Commun Signal

Date 2024 Jul 1

PMID 38946722

Authors

Preethi Chandrasekaran

Ralf Weiskirchen

Affiliations

Soon will be listed here.

Abstract

Obesity, a rapidly expanding epidemic worldwide, is known to exacerbate many medical conditions, making it a significant factor in multiple diseases and their associated complications. This threatening epidemic is linked to various harmful conditions such as type 2 diabetes mellitus, hypertension, metabolic dysfunction-associated steatotic liver disease, polycystic ovary syndrome, cardiovascular diseases (CVDs), dyslipidemia, and cancer. The rise in urbanization and sedentary lifestyles creates an environment that fosters obesity, leading to both psychosocial and medical complications. To identify individuals at risk and ensure timely treatment, it is crucial to have a better understanding of the pathophysiology of obesity and its comorbidities. This comprehensive review highlights the relationship between obesity and obesity-associated complications, including type 2 diabetes, hypertension, (CVDs), dyslipidemia, polycystic ovary syndrome, metabolic dysfunction-associated steatotic liver disease, gastrointestinal complications, and obstructive sleep apnea. It also explores the potential mechanisms underlying these associations. A thorough analysis of the interplay between obesity and its associated complications is vital in developing effective therapeutic strategies to combat the exponential increase in global obesity rates and mitigate the deadly consequences of this polygenic condition.

Citing Articles

Cathelicidin: Insights into Its Impact on Metabolic Syndrome and Chronic Inflammation.

Popa A, Gherasim A, Caba L, Nita O, Graur M, Mihalache L Metabolites. 2024; 14(12).

PMID: 39728453 PMC: 11676726. DOI: 10.3390/metabo14120672.

Pre-operative DNA methylation marks as predictors of weight loss outcomes after sleeve gastrectomy.

Paz-Lopez G, Linares-Pineda T, Gonzalez-Jimenez A, Sancho-Marin R, Ocana-Wilhelmi L, Tinahones F Mol Metab. 2024; 92:102087.

PMID: 39724958 PMC: 11780120. DOI: 10.1016/j.molmet.2024.102087.

Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.

Guo X, Zuo Z, Wang X, Sun Y, Xu D, Liu G Cardiooncology. 2024; 10(1):92.

PMID: 39716319 PMC: 11665102. DOI: 10.1186/s40959-024-00298-y.

Fidelity of BMI, Waist, and Waist-to-Height Ratio as Adiposity Measures in Normoglycemic Black vs White American Adults.

Liu Z, Asuzu P, Patel A, Wan J, Dagogo-Jack S J Endocr Soc. 2024; 9(1):bvae202.

PMID: 39610379 PMC: 11604086. DOI: 10.1210/jendso/bvae202.

Pre-Transplant Dual-Energy X-ray Absorptiometry (DXA)-Derived Body Composition Measures as Predictors of Treatment Outcomes and Early Post-Transplant Complications in Patients with Multiple Myeloma (MM) Treated with Autologous Hematopoietic Stem....

Jablonowska-Babij P, Jedrzejuk D, Majcherek M, Szeremet A, Karasek M, Kuszczak B J Clin Med. 2024; 13(19).

PMID: 39408047 PMC: 11478116. DOI: 10.3390/jcm13195987.

References

Han J, Wu J, Silke J . An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling. F1000Res. 2020; 9. PMC: 7324945. DOI: 10.12688/f1000research.22092.1. View

Alpert M, Omran J, Bostick B . Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function. Curr Obes Rep. 2016; 5(4):424-434. DOI: 10.1007/s13679-016-0235-6. View

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

OReilly M, House P, Tomlinson J . Understanding androgen action in adipose tissue. J Steroid Biochem Mol Biol. 2014; 143:277-84. DOI: 10.1016/j.jsbmb.2014.04.008. View

Popoviciu M, Paduraru L, Yahya G, Metwally K, Cavalu S . Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023; 24(13). PMC: 10341852. DOI: 10.3390/ijms241310449. View

Kadowaki T, Isendahl J, Khalid U, Lee S, Nishida T, Ogawa W . Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022; 10(3):193-206. DOI: 10.1016/S2213-8587(22)00008-0. View

Keane K, Cruzat V, Carlessi R, Homem de Bittencourt Jr P, Newsholme P . Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance and β-Cell Dysfunction. Oxid Med Cell Longev. 2015; 2015:181643. PMC: 4516838. DOI: 10.1155/2015/181643. View

Hall J, do Carmo J, da Silva A, Wang Z, Hall M . Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019; 15(6):367-385. PMC: 7278043. DOI: 10.1038/s41581-019-0145-4. View

Woo J, Koziol-White C, Panettieri Jr R, Jude J . TGF-β: The missing link in obesity-associated airway diseases?. Curr Res Pharmacol Drug Discov. 2021; 2:100016. PMC: 8663968. DOI: 10.1016/j.crphar.2021.100016. View

10.

Ringel A, Drijvers J, Baker G, Catozzi A, Garcia-Canaveras J, Gassaway B . Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020; 183(7):1848-1866.e26. PMC: 8064125. DOI: 10.1016/j.cell.2020.11.009. View

11.

Deleyto-Seldas N, Efeyan A . The mTOR-Autophagy Axis and the Control of Metabolism. Front Cell Dev Biol. 2021; 9:655731. PMC: 8281972. DOI: 10.3389/fcell.2021.655731. View

12.

Wang Z, Zhu M, Wang M, Gao Y, Zhang C, Liu S . Integrated Multiomic Analysis Reveals the High-Fat Diet Induced Activation of the MAPK Signaling and Inflammation Associated Metabolic Cascades via Histone Modification in Adipose Tissues. Front Genet. 2021; 12:650863. PMC: 8273343. DOI: 10.3389/fgene.2021.650863. View

13.

Wang D, Nan N, Bing H, He B . Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023; 14:1241734. PMC: 10501797. DOI: 10.3389/fendo.2023.1241734. View

14.

Solinas G, Becattini B . JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol Metab. 2017; 6(2):174-184. PMC: 5279903. DOI: 10.1016/j.molmet.2016.12.001. View

15.

Aune D, Norat T, Vatten L . Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol. 2015; 30(9):1009-19. DOI: 10.1007/s10654-015-0081-y. View

16.

Straub L, Scherer P . Metabolic Messengers: Adiponectin. Nat Metab. 2020; 1(3):334-339. PMC: 7357716. DOI: 10.1038/s42255-019-0041-z. View

17.

Yanai H, Yoshida H . Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019; 20(5). PMC: 6429491. DOI: 10.3390/ijms20051190. View

18.

Petersen M, Shulman G . Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98(4):2133-2223. PMC: 6170977. DOI: 10.1152/physrev.00063.2017. View

19.

Gao Q, Wolfgang M, Neschen S, Morino K, Horvath T, Shulman G . Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci U S A. 2004; 101(13):4661-6. PMC: 384803. DOI: 10.1073/pnas.0303992101. View

20.

Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R . Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022; 7(1):298. PMC: 9420733. DOI: 10.1038/s41392-022-01149-x. View